Small molecule control of chromatin remodeling

Chemistry and Biology

Volumn 21, Issue 9, 2014, Pages 1196-1210

  Finley, Aidan ^a   Copeland, Robert A ^a  

^a EPIZYME INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; BROMODOMAIN INHIBITOR; CELL PROTEIN; CHROMATIN MODIFYING PROTEIN; DNA; HISTONE; HISTONE ACETYLTRANSFERASE INHIBITOR; HISTONE DEACETYLASE INHIBITOR; LYSINE DEMETHYLASE INHIBITOR; PROTEIN METHYLTRANSFERASE INHIBITOR; UNCLASSIFIED DRUG; CHROMATIN; ENZYME INHIBITOR; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE; HISTONE DEMETHYLASE; METHYLTRANSFERASE; MOLECULAR LIBRARY;

CHROMATIN; CHROMATIN ASSEMBLY AND DISASSEMBLY; DISEASES; GENE CONTROL; HISTONE ACETYLATION; HISTONE METHYLATION; HUMAN; HYDROLYSIS; NONHUMAN; PROTEIN NUCLEIC ACID INTERACTION; PROTEIN PROCESSING; REVIEW; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DRUG EFFECTS; METABOLISM; METHYLATION; MOLECULAR LIBRARY; PHARMACOLOGY;

CHROMATIN; CHROMATIN ASSEMBLY AND DISASSEMBLY; ENZYME INHIBITORS; HISTONE ACETYLTRANSFERASES; HISTONE DEACETYLASES; HISTONE DEMETHYLASES; HISTONES; HUMANS; METHYLATION; METHYLTRANSFERASES; SMALL MOLECULE LIBRARIES;

EID: 84910082388     PISSN: 10745521     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.chembiol.2014.07.024     Document Type: Review

References (91)

1. M. Allan, S. Manku, E. Therrien, N. Nguyen, S. Styhler, M.F. Robert, A.C. Goulet, A.J. Petschner, G. Rahil, and A. Robert Macleod N-Benzyl-1-heteroaryl-3-(trifluoromethyl)-1H-pyrazole-5-carboxamides as inhibitors of co-activator associated arginine methyltransferase 1 (CARM1) Bioorg. Med. Chem. Lett. 19 2009 1218 1223
2. C.D. Allis, T. Jenuwein, D. Reinberg, and M. Caparros Epigenetics 2007 Cold Spring Harbor Press New York
3. F. Andreoli, A.J. Barbosa, M.D. Parenti, and A. Del Rio Modulation of epigenetic targets for anticancer therapy: clinicopathological relevance, structural data and drug discovery perspectives Curr. Pharm. Des. 19 2013 578 613
4. C.H. Arrowsmith, C. Bountra, P.V. Fish, K. Lee, and M. Schapira Epigenetic protein families: a new frontier for drug discovery Nat. Rev. Drug Discov. 11 2012 384 400
5. S. Balasubramanian, J. Ramos, W. Luo, M. Sirisawad, E. Verner, and J.J. Buggy A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas Leukemia 22 2008 1026 1034
6. A. Basavapathruni, L. Jin, S.R. Daigle, C.R. Majer, C.A. Therkelsen, T.J. Wigle, K.W. Kuntz, R. Chesworth, R.M. Pollock, and M.P. Scott Conformational adaptation drives potent, selective and durable inhibition of the human protein methyltransferase DOT1L Chem. Biol. Drug Des. 80 2012 971 980
7. S.B. Baylin DNA methylation and gene silencing in cancer Nat. Clin. Pract. Oncol. 2 Suppl 1 2005 S4 S11
8. S.B. Baylin, and P.A. Jones A decade of exploring the cancer epigenome - biological and translational implications Nat. Rev. Cancer 11 2011 726 734
9. E.M. Bowers, G. Yan, C. Mukherjee, A. Orry, L. Wang, M.A. Holbert, N.T. Crump, C.A. Hazzalin, G. Liszczak, and H. Yuan Virtual ligand screening of the p300/CBP histone acetyltransferase: identification of a selective small molecule inhibitor Chem. Biol. 17 2010 471 482
10. B.W. Bridle, L. Chen, C.G. Lemay, J.S. Diallo, J. Pol, A. Nguyen, A. Capretta, R. He, J.L. Bramson, and J.C. Bell HDAC inhibition suppresses primary immune responses, enhances secondary immune responses, and abrogates autoimmunity during tumor immunotherapy Mol. Ther. 21 2013 887 894
11. R.M. Campbell, and P.J. Tummino Cancer epigenetics drug discovery and development: the challenge of hitting the mark J. Clin. Invest. 124 2014 64 69
12. B. Chang, Y. Chen, Y. Zhao, and R.K. Bruick JMJD6 is a histone arginine demethylase Science 318 2007 444 447
13. C.K. Collings, P.J. Waddell, and J.N. Anderson Effects of DNA methylation on nucleosome stability Nucleic Acids Res. 41 2013 2918 2931
14. R.A. Copeland Molecular pathways: protein methyltransferases in cancer Clin. Cancer Res. 19 2013 6344 6350
15. R.A. Copeland, M.E. Solomon, and V.M. Richon Protein methyltransferases as a target class for drug discovery Nat. Rev. Drug Discov. 8 2009 724 732
16. R.A. Copeland, E.J. Olhava, and M.P. Scott Targeting epigenetic enzymes for drug discovery Curr. Opin. Chem. Biol. 14 2010 505 510
17. R.A. Copeland, M.P. Moyer, and V.M. Richon Targeting genetic alterations in protein methyltransferases for personalized cancer therapeutics Oncogene 32 2013 939 946
18. G.L. Cuthbert, S. Daujat, A.W. Snowden, H. Erdjument-Bromage, T. Hagiwara, M. Yamada, R. Schneider, P.D. Gregory, P. Tempst, A.J. Bannister, and T. Kouzarides Histone deimination antagonizes arginine methylation Cell 118 2004 545 553
19. S.R. Daigle, E.J. Olhava, C.A. Therkelsen, C.R. Majer, C.J. Sneeringer, J. Song, L.D. Johnston, M.P. Scott, J.J. Smith, and Y. Xiao Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor Cancer Cell 20 2011 53 65
20. S.R. Daigle, E.J. Olhava, C.A. Therkelsen, A. Basavapathruni, L. Jin, P.A. Boriack-Sjodin, C.J. Allain, C.R. Klaus, A. Raimondi, and M.P. Scott Potent inhibition of DOT1L as treatment of MLL-fusion leukemia Blood 122 2013 1017 1025
21. F.J. Dekker, T. van den Bosch, and N.I. Martin Small molecule inhibitors of histone acetyltransferases and deacetylases are potential drugs for inflammatory diseases Drug Discov. Today 19 2014 654 660
22. A. Dey, F. Chitsaz, A. Abbasi, T. Misteli, and K. Ozato The double bromodomain protein Brd4 binds to acetylated chromatin during interphase and mitosis Proc. Natl. Acad. Sci. USA 100 2003 8758 8763
23. S. Dhe-Paganon, F. Syeda, and L. Park DNA methyl transferase 1: regulatory mechanisms and implications in health and disease Int J Biochem Mol Biol 2 2011 58 66
24. A.D. Ferguson, N.A. Larsen, T. Howard, H. Pollard, I. Green, C. Grande, T. Cheung, R. Garcia-Arenas, S. Cowen, and J. Wu Structural basis of substrate methylation and inhibition of SMYD2 Structure 19 2011 1262 1273
25. P. Filippakopoulos, and S. Knapp Targeting bromodomains: epigenetic readers of lysine acetylation Nat. Rev. Drug Discov. 13 2014 337 356
26. P. Filippakopoulos, J. Qi, S. Picaud, Y. Shen, W.B. Smith, O. Fedorov, E.M. Morse, T. Keates, T.T. Hickman, and I. Felletar Selective inhibition of BET bromodomains Nature 468 2010 1067 1073
27. P. Filippakopoulos, S. Picaud, M. Mangos, T. Keates, J.P. Lambert, D. Barsyte-Lovejoy, I. Felletar, R. Volkmer, S. Müller, and T. Pawson Histone recognition and large-scale structural analysis of the human bromodomain family Cell 149 2012 214 231
28. M.S. Finnin, J.R. Donigian, A. Cohen, V.M. Richon, R.A. Rifkind, P.A. Marks, R. Breslow, and N.P. Pavletich Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors Nature 401 1999 188 193
29. F. Forneris, C. Binda, M.A. Vanoni, A. Mattevi, and E. Battaglioli Histone demethylation catalysed by LSD1 is a flavin-dependent oxidative process FEBS Lett. 579 2005 2203 2207
30. C.A. French Demystified molecular pathology of NUT midline carcinomas J. Clin. Pathol. 63 2010 492 496
31. D.R. Friedmann, and R. Marmorstein Structure and mechanism of non-histone protein acetyltransferase enzymes FEBS J. 280 2013 5570 5581
32. S.M. Frumm, Z.P. Fan, K.N. Ross, J.R. Duvall, S. Gupta, L. VerPlank, B.C. Suh, E. Holson, F.F. Wagner, and W.B. Smith Selective HDAC1/HDAC2 inhibitors induce neuroblastoma differentiation Chem. Biol. 20 2013 713 725
33. R. Furumai, A. Matsuyama, N. Kobashi, K.H. Lee, M. Nishiyama, H. Nakajima, A. Tanaka, Y. Komatsu, N. Nishino, M. Yoshida, and S. Horinouchi FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases Cancer Res. 62 2002 4916 4921
34. I.V. Gregoretti, Y.M. Lee, and H.V. Goodson Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis J. Mol. Biol. 338 2004 17 31
35. S.R. Haynes, C. Dollard, F. Winston, S. Beck, J. Trowsdale, and I.B. Dawid The bromodomain: a conserved sequence found in human, Drosophila and yeast proteins Nucleic Acids Res. 20 1992 2603
36. K. Helin, and D. Dhanak Chromatin proteins and modifications as drug targets Nature 502 2013 480 488
37. S.C. Hodawadekar, and R. Marmorstein Chemistry of acetyl transfer by histone modifying enzymes: structure, mechanism and implications for effector design Oncogene 26 2007 5528 5540
38. R. Holliday Mechanisms for the control of gene activity during development Biol. Rev. Camb. Philos. Soc. 65 1990 431 471
39. T. Huynh, Z. Chen, S. Pang, J. Geng, T. Bandiera, S. Bindi, P. Vianello, F. Roletto, S. Thieffine, and A. Galvani Optimization of pyrazole inhibitors of coactivator associated arginine methyltransferase 1 (CARM1) Bioorg. Med. Chem. Lett. 19 2009 2924 2927
40. L.I. James, and S.V. Frye Targeting chromatin readers Clin. Pharmacol. Ther. 93 2013 312 314
41. L.I. James, D. Barsyte-Lovejoy, N. Zhong, L. Krichevsky, V.K. Korboukh, J.M. Herold, C.J. MacNevin, J.L. Norris, C.A. Sagum, and W. Tempel Discovery of a chemical probe for the L3MBTL3 methyllysine reader domain Nat. Chem. Biol. 9 2013 184 191
42. L.D. Johnston, S.K. Knutston, N. Warholic, C.R. Klaus, T.J. Wigle, D. Iwanowicz, B.A. Littlefield, M. Porter Scott, J.J. Smith, and S.R. Daigle EZH2 inhibitor EPZ-6438 synergizes with anti-lymphoma therapies in preclinical models Blood 122 2013 4416
43. C.R. Klaus, S.R. Daigle, D. Iwanowics, D. Johnston, C.R. Klaus, M. Porter Scott, N. Warholic, S.K. Knutston, J.J. Smith, and T.J. Wigle DOT1L inhibitor EPZ-5676 displays synergistic antiproliferative activity in combination with standard of care drugs or DNA hypomethylating agents in MLL-rearranged leukemia cells Blood 122 2013 3930
44. S.K. Knutson, N.M. Warholic, T.J. Wigle, C.R. Klaus, C.J. Allain, A. Raimondi, M. Porter Scott, R. Chesworth, M.P. Moyer, and R.A. Copeland Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2 Proc. Natl. Acad. Sci. USA 110 2013 7922 7927
45. S.K. Knutson, S. Kawano, Y. Minoshima, N.M. Warholic, K.C. Huang, Y. Xiao, T. Kadowaki, M. Uesugi, G. Kuznetsov, and N. Kumar Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma Mol. Cancer Ther. 13 2014 842 854
46. M. Kollareddy, D. Zheleva, P. Dzubak, P.S. Brahmkshatriya, M. Lepsik, and M. Hajduch Aurora kinase inhibitors: progress towards the clinic Invest. New Drugs 30 2012 2411 2432
47. R.G. Kruger, H. Mohammad, K. Smitheman, M. Cusan, Y. Liu, M. Pappalardi, K. Federowicz, G. Van Aller, J. Kasparec, and X. Tian Inhibition of LSD1 as a therapeutic strategy for the treatment of acute myeloid leukemia Blood 122 2013 3964
48. L. Kruidenier, C.W. Chung, Z. Cheng, J. Liddle, K. Che, G. Joberty, M. Bantscheff, C. Bountra, A. Bridges, and H. Diallo A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response Nature 488 2012 404 408
49. A.J. Kuo, J. Song, P. Cheung, S. Ishibe-Murakami, S. Yamazoe, J.K. Chen, D.J. Patel, and O. Gozani The BAH domain of ORC1 links H4K20me2 to DNA replication licensing and Meier-Gorlin syndrome Nature 484 2012 115 119
50. M. Kurita, T. Holloway, A. García-Bea, A. Kozlenkov, A.K. Friedman, J.L. Moreno, M. Heshmati, S.A. Golden, P.J. Kennedy, and N. Takahashi HDAC2 regulates atypical antipsychotic responses through the modulation of mGlu2 promoter activity Nat. Neurosci. 15 2012 1245 1254
51. K.K. Lee, and J.L. Workman Histone acetyltransferase complexes: one size doesn't fit all Nat. Rev. Mol. Cell Biol. 8 2007 284 295
52. X. Liu, L. Wang, K. Zhao, P.R. Thompson, Y. Hwang, R. Marmorstein, and P.A. Cole The structural basis of protein acetylation by the p300/CBP transcriptional coactivator Nature 451 2008 846 850
53. F. Liu, D. Barsyte-Lovejoy, F. Li, Y. Xiong, V. Korboukh, X.P. Huang, A. Allali-Hassani, W.P. Janzen, B.L. Roth, and S.V. Frye Discovery of an in vivo chemical probe of the lysine methyltransferases G9a and GLP J. Med. Chem. 56 2013 8931 8942
54. P.M. Lombardi, K.E. Cole, D.P. Dowling, and D.W. Christianson Structure, mechanism, and inhibition of histone deacetylases and related metalloenzymes Curr. Opin. Struct. Biol. 21 2011 735 743
55. T. Maes, I. Tirapu, C. Mascaro, A. Ortega, A. Estiarte, V. Nuria, J. Castro-Palomino, C. Buesa Arjol, G. Kurz, and O. Genomics Preclinical characterization of a potent and selective inhibitor of the histone demethylase KDM1A for MLL leukemia J. Clin. Oncol. 31 2013 e13543
56. B.S. Mann, J.R. Johnson, M.H. Cohen, R. Justice, and R. Pazdur FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma Oncologist 12 2007 1247 1252
57. R. Marmorstein Structure and function of histone acetyltransferases Cell. Mol. Life Sci. 58 2001 693 703
58. M.T. McCabe, H.M. Ott, G. Ganji, S. Korenchuk, C. Thompson, G.S. Van Aller, Y. Liu, A.P. Graves, A. Della Pietra 3rd, and E. Diaz EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations Nature 492 2012 108 112
59. J.C. Milne, and J.M. Denu The Sirtuin family: therapeutic targets to treat diseases of aging Curr. Opin. Chem. Biol. 12 2008 11 17
60. O. Mirguet, R. Gosmini, J. Toum, C.A. Clément, M. Barnathan, J.M. Brusq, J.E. Mordaunt, R.M. Grimes, M. Crowe, and O. Pineau Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains J. Med. Chem. 56 2013 7501 7515
61. D. Moschidou, S. Mukherjee, M.P. Blundell, K. Drews, G.N. Jones, H. Abdulrazzak, B. Nowakowska, A. Phoolchund, K. Lay, and T.S. Ramasamy Valproic acid confers functional pluripotency to human amniotic fluid stem cells in a transgene-free approach Mol. Ther. 20 2012 1953 1967
62. S. Mujtaba, L. Zeng, and M.M. Zhou Structure and acetyl-lysine recognition of the bromodomain Oncogene 26 2007 5521 5527
63. T.T. Onder, N. Kara, A. Cherry, A.U. Sinha, N. Zhu, K.M. Bernt, P. Cahan, B.O. Marcarci, J. Unternaehrer, and P.B. Gupta Chromatin-modifying enzymes as modulators of reprogramming Nature 483 2012 598 602
64. D.J. Owen, P. Ornaghi, J.C. Yang, N. Lowe, P.R. Evans, P. Ballario, D. Neuhaus, P. Filetici, and A.A. Travers The structural basis for the recognition of acetylated histone H4 by the bromodomain of histone acetyltransferase gcn5p EMBO J. 19 2000 6141 6149
65. M. Ptashne Epigenetics: core misconcept Proc. Natl. Acad. Sci. USA 110 2013 7101 7103
66. S. Picaud, C. Wells, I. Felletar, D. Brotherton, S. Martin, P. Savitsky, B. Diez-Dacal, M. Philpott, C. Bountra, and H. Lingard RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain Proc. Natl. Acad. Sci. USA 110 2013 19754 19759
67. H.M. Prince, M.J. Bishton, and S.J. Harrison Clinical studies of histone deacetylase inhibitors Clin. Cancer Res. 15 2009 3958 3969
68. J.C. Rice, and C.D. Allis Histone methylation versus histone acetylation: new insights into epigenetic regulation Curr. Opin. Cell Biol. 13 2001 263 273
69. V.M. Richon, D. Johnston, C.J. Sneeringer, L. Jin, C.R. Majer, K. Elliston, L.F. Jerva, M.P. Scott, and R.A. Copeland Chemogenetic analysis of human protein methyltransferases Chem. Biol. Drug Des. 78 2011 199 210
70. C. Rivera, Z.A. Gurard-Levin, G. Almouzni, and A. Loyola Histone lysine methylation and chromatin replication Biochim. Biophys. Acta 2014 10.1016/j.bbagrm.2014.03.009 Published online March 28, 2014
71. D. Rossetto, N. Avvakumov, and J. Côté Histone phosphorylation: a chromatin modification involved in diverse nuclear events Epigenetics 7 2012 1098 1108
72. S.Y. Roth, J.M. Denu, and C.D. Allis Histone acetyltransferases Annu. Rev. Biochem. 70 2001 81 120
73. L. Santo, T. Hideshima, A.L. Kung, J.C. Tseng, D. Tamang, M. Yang, M. Jarpe, J.H. van Duzer, R. Mazitschek, and W.C. Ogier Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma Blood 119 2012 2579 2589
74. A.H. Shain, and J.R. Pollack The spectrum of SWI/SNF mutations, ubiquitous in human cancers PLoS ONE 8 2013 e55119
75. A. Siarheyeva, G. Senisterra, A. Allali-Hassani, A. Dong, E. Dobrovetsky, G.A. Wasney, I. Chau, R. Marcellus, T. Hajian, and F. Liu An allosteric inhibitor of protein arginine methyltransferase 3 Structure 20 2012 1425 1435
76. E.B. Stelow A review of NUT midline carcinoma Head Neck Pathol. 5 2011 31 35
77. T. Suganuma, and J.L. Workman MAP kinases and histone modification J. Mol. Cell Biol. 4 2012 348 350
78. R.F. Sweis, M. Pliushchev, P.J. Brown, J. Guo, F. Li, D. Maag, A.M. Petros, N.B. Soni, C. Tse, and M. Vedadi Discovery and development of potent and selective inhibitors of histone methyltransferase g9a ACS Med Chem Lett 5 2014 205 209
79. L. Tang, E. Nogales, and C. Ciferri Structure and function of SWI/SNF chromatin remodeling complexes and mechanistic implications for transcription Prog. Biophys. Mol. Biol. 102 2010 122 128
80. Y. Tsukada, J. Fang, H. Erdjument-Bromage, M.E. Warren, C.H. Borchers, P. Tempst, and Y. Zhang Histone demethylation by a family of JmjC domain-containing proteins Nature 439 2006 811 816
81. G.S. Van Aller, M.B. Pappalardi, H.M. Ott, E. Diaz, M. Brandt, B.J. Schwartz, W.H. Miller, D. Dhanak, M.T. McCabe, and S.K. Verma Long residence time inhibition of EZH2 in activated polycomb repressive complex 2 ACS Chem. Biol. 9 2014 622 629
82. C.T. Walsh Posttranslational Modification of Proteins: Expanding Nature's Inventory 2006 Roberts & Company Englewood, CO
83. Y. Wang, J. Wysocka, J. Sayegh, Y.-H. Lee, J.R. Perlin, L. Leonelli, L.S. Sonbuchner, C.H. McDonald, R.G. Cook, and Y. Dou Human PAD4 regulates histone arginine methylation levels via demethylimination Science 306 2004 279 283
84. E. Wang, S. Kawaoka, M. Yu, J. Shi, T. Ni, W. Yang, J. Zhu, R.G. Roeder, and C.R. Vakoc Histone H2B ubiquitin ligase RNF20 is required for MLL-rearranged leukemia Proc. Natl. Acad. Sci. USA 110 2013 3901 3906
85. X. Wang, J.R. Haswell, and C.W. Roberts Molecular pathways: SWI/SNF (BAF) complexes are frequently mutated in cancer - mechanisms and potential therapeutic insights Clin. Cancer Res. 20 2014 21 27
86. T.J. Wigle, and R.A. Copeland Drugging the human methylome: an emerging modality for reversible control of aberrant gene transcription Curr. Opin. Chem. Biol. 17 2013 369 378
87. B.J. Wilkins, N.A. Rall, Y. Ostwal, T. Kruitwagen, K. Hiragami-Hamada, M. Winkler, Y. Barral, W. Fischle, and H. Neumann A cascade of histone modifications induces chromatin condensation in mitosis Science 343 2014 77 80
88. B.G. Wilson, and C.W. Roberts SWI/SNF nucleosome remodellers and cancer Nat. Rev. Cancer 11 2011 481 492
89. B.G. Wilson, X. Wang, X. Shen, E.S. McKenna, M.E. Lemieux, Y.-J. Cho, E.C. Koellhoffer, S.L. Pomeroy, S.H. Orkin, and C.W.M. Roberts Epigenetic antagonism between polycomb and SWI/SNF complexes during oncogenic transformation Cancer Cell 18 2010 316 328
90. B.G. Wilson, K.C. Helming, X. Wang, Y. Kim, F. Vazquez, Z. Jagani, W.C. Hahn, and C.W. Roberts Residual complexes containing SMARCA2 (BRM) underlie the oncogenic drive of SMARCA4 (BRG1) mutation Mol. Cell. Biol. 34 2014 1136 1144
91. Y. Zheng, S.M. Sweet, R. Popovic, E. Martinez-Garcia, J.D. Tipton, P.M. Thomas, J.D. Licht, and N.L. Kelleher Total kinetic analysis reveals how combinatorial methylation patterns are established on lysines 27 and 36 of histone H3 Proc. Natl. Acad. Sci. USA 109 2012 13549 13554